{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:13:02Z","timestamp":1793167982752,"version":"4.5.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec015\">\n<jats:title>Background<\/jats:title>\n<jats:p>Bile acid sequestrants (BASs), including cholestyramine, colestipol, and colesevelam, are widely used in endocrine and gastrointestinal disorders. However, their long-term safety remains under-characterized. This study leveraged real-world pharmacovigilance data to evaluate underreported and subclass-specific adverse events (AEs) associated with BASs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec016\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We analyzed 5,286 AE reports related to BASs from the FDA Adverse Event Reporting System (2004\u20132024) using four disproportionality methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). AE signals were assessed at both the System Organ Class (SOC) and Preferred Term (PT) levels. Time-to-onset (TTO) analysis was also performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec017\">\n<jats:title>Results<\/jats:title>\n<jats:p>All three BASs showed prominent gastrointestinal AEs. Cholestyramine was notably associated with oropharyngeal irritation (e.g., throat irritation, ROR\u2009=\u200921.89; oropharyngeal discomfort, ROR\u2009=\u200936.53), while colestipol presented mechanical risks such as dysphagia (ROR\u2009=\u200921.51) and choking (ROR\u2009=\u200967.44). Colesevelam exhibited musculoskeletal toxicity, including myalgia (ROR\u2009=\u20094.74) and muscle spasms (ROR\u2009=\u20093.43). Consensus signals across all methods further revealed novel AEs such as dysgeusia, dental abnormalities, gastroesophageal reflux disease, and fecaloma. TTO analysis showed that most AEs occurred within the first month of therapy, with 15\u201316% persisting beyond 6 months.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec018\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This large-scale FAERS study updates the safety profiles of BASs, highlighting distinct risk patterns and delayed complications. The findings support personalized monitoring strategies that consider both drug-specific characteristics and temporal AE patterns.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0328371","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:23:22Z","timestamp":1752600202000},"page":"e0328371","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system"],"prefix":"10.1371","volume":"20","author":[{"given":"Wangqi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-0067","authenticated-orcid":true,"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"6","key":"pone.0328371.ref001","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/gels9060500","article-title":"Bile Acid Sequestrants Based on Natural and Synthetic Gels","volume":"9","author":"M-C Stanciu","year":"2023","journal-title":"Gels"},{"issue":"12","key":"pone.0328371.ref002","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14656566.2022.2112945","article-title":"Colesevelam \u2013 a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia","volume":"23","author":"O Esan","year":"2022","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"2","key":"pone.0328371.ref003","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00125-011-2382-3","article-title":"Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study","volume":"55","author":"C Beysen","year":"2011","journal-title":"Diabetologia"},{"issue":"4","key":"pone.0328371.ref004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2468-1253(22)00401-0","article-title":"Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial","volume":"8","author":"C Borup","year":"2023","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"15","key":"pone.0328371.ref005","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and Treatment of Pruritus in Cholestasis","volume":"68","author":"AE Kremer","year":"2008","journal-title":"Drugs"},{"issue":"1","key":"pone.0328371.ref006","article-title":"Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis","volume":"13","author":"B Li","year":"2021","journal-title":"Gut Microbes"},{"issue":"9","key":"pone.0328371.ref007","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/gutjnl-2017-314553","article-title":"Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2\u2212\/\u2212 mice by modulating composition, signalling and excretion of faecal bile acids","volume":"67","author":"CD Fuchs","year":"2018","journal-title":"Gut"},{"issue":"11","key":"pone.0328371.ref008","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.crohns.2014.05.009","article-title":"Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn\u2019s disease: A randomized, double-blind, placebo-controlled study","volume":"8","author":"F Beigel","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"5","key":"pone.0328371.ref009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea\u2010predominant irritable bowel syndrome","volume":"41","author":"M Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0328371.ref010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12072-022-10296-w","article-title":"Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice","volume":"16","author":"P Hartmann","year":"2022","journal-title":"Hepatol Int"},{"issue":"12","key":"pone.0328371.ref011","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.cgh.2023.04.031","article-title":"Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing","volume":"21","author":"J Tome","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"01","key":"pone.0328371.ref012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-0029-1241195","article-title":"Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes","volume":"42","author":"AB Goldfine","year":"2009","journal-title":"Horm Metab Res"},{"issue":"2","key":"pone.0328371.ref013","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.2013.752813","article-title":"A review of the efficacy and safety of oral antidiabetic drugs","volume":"12","author":"SA Stein","year":"2012","journal-title":"Expert Opinion on Drug Safety"},{"issue":"6","key":"pone.0328371.ref014","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/009127009203200608","article-title":"Cholestyramine\u2010Induced Hyperchloremic Metabolic Acidosis","volume":"32","author":"Jr Scheel PJ","year":"1992","journal-title":"The Journal of Clinical Pharma"},{"issue":"1","key":"pone.0328371.ref015","first-page":"19","article-title":"Vitamin K deficiency and bleeding after long-term use of cholestyramine","volume":"61","author":"K Vroonhof","year":"2003","journal-title":"Neth J Med"},{"issue":"10","key":"pone.0328371.ref016","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","article-title":"Ursodeoxycholic acid \u2014 adverse effects and drug interactions","volume":"18","author":"W Hempfling","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"pone.0328371.ref017","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM196906052802307","article-title":"Intestinal Obstruction Associated with Cholestyramine Therapy","volume":"280","author":"MI Cohen","year":"1969","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0328371.ref018","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.3390\/ijms23115935","article-title":"Effects of Bile Acid Modulation by Dietary Fat, Cholecystectomy, and Bile Acid Sequestrant on Energy, Glucose, and Lipid Metabolism and Gut Microbiota in Mice","volume":"23","author":"S Park","year":"2022","journal-title":"IJMS"},{"issue":"2","key":"pone.0328371.ref019","first-page":"172","article-title":"Osimertinib-Induced Cardiotoxicity","volume":"1","author":"K Anand","year":"2019","journal-title":"JACC: CardioOncology"},{"key":"pone.0328371.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2446430","article-title":"Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database","author":"X Li","year":"2025","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"pone.0328371.ref021","article-title":"Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study","volume":"26","author":"X Li","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"pone.0328371.ref022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Z-Y Luo","year":"2024","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"pone.0328371.ref023","article-title":"Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database","volume":"15","author":"B Zhu","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0328371.ref024","doi-asserted-by":"crossref","DOI":"10.1186\/s13293-019-0265-3","article-title":"The influence of biological sex and sex hormones on bile acid synthesis and cholesterol homeostasis","volume":"10","author":"T Phelps","year":"2019","journal-title":"Biol Sex Differ"},{"key":"pone.0328371.ref025","article-title":"The Pathological Mechanisms of Estrogen-Induced Cholestasis: Current Perspectives","volume":"12","author":"Y Zu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"pone.0328371.ref026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.11.035","article-title":"Impact of Bile Acid Diarrhea in Patients With Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life","volume":"20","author":"J BouSaba","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"10266","key":"pone.0328371.ref027","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"A Lleo","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"pone.0328371.ref028","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ejendo\/lvae033","article-title":"Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling","volume":"190","author":"IM Gether","year":"2024","journal-title":"European Journal of Endocrinology"},{"key":"pone.0328371.ref029","doi-asserted-by":"crossref","first-page":"101744","DOI":"10.1016\/j.arr.2022.101744","article-title":"Differential gut microbiota and intestinal permeability between frail and healthy older adults: A systematic review","volume":"82","author":"NH Rashidah","year":"2022","journal-title":"Ageing Research Reviews"},{"key":"pone.0328371.ref030","doi-asserted-by":"crossref","DOI":"10.31128\/AJGP-08-23-6928","article-title":"Adult-onset dysphagia","volume":"53","author":"F Chuang","year":"2024","journal-title":"Aust J Gen Pract"},{"key":"pone.0328371.ref031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/TCRM.S414460","article-title":"Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review","volume":"19","author":"H Liu","year":"2023","journal-title":"TCRM"},{"issue":"9","key":"pone.0328371.ref032","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"Interactions of Warfarin with Drugs and Food","volume":"121","author":"PS Wells","year":"1994","journal-title":"Ann Intern Med"},{"issue":"3","key":"pone.0328371.ref033","doi-asserted-by":"crossref","first-page":"252","DOI":"10.7861\/clinmedicine.15-3-252","article-title":"Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy","volume":"15","author":"O Orekoya","year":"2015","journal-title":"Clinical Medicine"},{"issue":"11","key":"pone.0328371.ref034","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.clinthera.2009.11.027","article-title":"Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: A retrospective chart review and patient questionnaire","volume":"31","author":"L Wedlake","year":"2009","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"pone.0328371.ref035","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-014-0482-4","article-title":"Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes","volume":"14","author":"M Hansen","year":"2014","journal-title":"Curr Diab Rep"},{"key":"pone.0328371.ref036","first-page":"1191","volume-title":"Bile Acid Metabolism and Signaling. Comprehensive Physiology","author":"JYL Chiang","year":"2013"},{"issue":"3","key":"pone.0328371.ref037","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"JYL Chiang","year":"2020","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"key":"pone.0328371.ref038","doi-asserted-by":"crossref","first-page":"108238","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"J Cai","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"issue":"5","key":"pone.0328371.ref039","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41575-024-00896-2","article-title":"Another renaissance for bile acid gastrointestinal microbiology","volume":"21","author":"JM Ridlon","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"pone.0328371.ref040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/2050640616662432","article-title":"Effects of conventional and a novel colonic\u2010release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea","volume":"5","author":"R Appleby","year":"2017","journal-title":"UEG Journal"},{"issue":"6","key":"pone.0328371.ref041","first-page":"609","article-title":"Hypoprothrombinemic hemorrhage due to cholestyramine therapy","volume":"134","author":"AM Shojania","year":"1986","journal-title":"CMAJ"},{"key":"pone.0328371.ref042","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.2147\/RMHP.S316897","article-title":"A Literature Review of the Potential Impact of Medication on Vitamin D Status","author":"M Wakeman","year":"2021","journal-title":"RMHP"},{"issue":"4","key":"pone.0328371.ref043","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.mayocp.2022.12.002","article-title":"Acquired Disorders of Hypomagnesemia","volume":"98","author":"MH Rosner","year":"2023","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"pone.0328371.ref044","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cgh.2009.10.020","article-title":"Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel Function","volume":"8","author":"ST Odunsi\u2013Shiyanbade","year":"2010","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"11","key":"pone.0328371.ref045","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3390\/cells9112481","article-title":"Drug Crystal-Related Gastrointestinal Complications Involve Crystal-Induced Release of Neutrophil and Monocyte Extracellular Traps","volume":"9","author":"T Kim","year":"2020","journal-title":"Cells"},{"issue":"9","key":"pone.0328371.ref046","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/17474124.2024.2402353","article-title":"Managing bile acid diarrhea: aspects of contention","volume":"18","author":"JRF Walters","year":"2024","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"12","key":"pone.0328371.ref047","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/j.1440-1746.2011.06805.x","article-title":"Functional characterization of genetic variants in the apical sodium\u2010dependent bile acid transporter (ASBT; SLC10A2)","volume":"26","author":"RH Ho","year":"2011","journal-title":"J of Gastro and Hepatol"},{"issue":"8","key":"pone.0328371.ref048","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/jn\/119.8.1100","article-title":"Interaction of Bile Acids, Phospholipids, Cholesterol and Triglyceride with Dietary Fibers in the Small Intestine of Rats","volume":"119","author":"K Ebihara","year":"1989","journal-title":"The Journal of Nutrition"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:23:44Z","timestamp":1752600224000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328371"}},"subtitle":[],"editor":[{"given":"Sharon","family":"DeMorrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328371","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}